Business Wire | Jul 22, 2020 04:20PM EDT

ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting

Jul. 22, 2020

DUBLIN--(BUSINESS WIRE)--Jul. 22, 2020--ICONplc(NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on July 21, 2020 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 9, 2020 and are available on the ICON plc website.

The final results of the voting are as follows:

RESOLUTION TOTAL VOTE VOTENUMBER RESOLUTION NUMBER OF VOTE FOR AGAINST WITHHELD VOTES

1.1 To re-elect Ms. Mary 45,375,290 45,047,124 313,139 15,027 Pendergast

1.2 To re-elect Professor 45,375,290 44,847,529 512,926 14,835 Hugh Brady

1.3 To re-elect Mr. R?n?n 45,375,290 44,886,771 473,815 14,704 Murphy

1.4 To re-elect Ms. Julie 45,375,290 45,352,908 6,707 15,675 O'Neill

2 To receive accounts 45,375,290 45,125,109 1,867 248,314 and reports

To authorise the3 fixing of the 45,375,290 41,855,932 3,504,170 15,188 auditors' remuneration

To authorise the4 Company to allot 45,375,290 45,327,330 37,054 10,906 shares

5** To disapply 45,375,290 45,337,113 23,998 14,179 pre-emption rights

To disapply pre-emption rights for6** funding capital 45,375,290 45,219,197 141,875 14,218 investment or acquisitions

To authorise the7** Company to make market 45,375,290 45,072,354 178,525 124,411 purchases of shares

To authorise the price range at which the8** Company can reissue 45,375,290 45,081,032 271,321 22,937 shares it holds as treasury shares

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON employed approximately 15,150 employees in 94 locations in 40 countries as at June 30, 2020. Further information is available at www.iconplc.com.

Source: ICON plc Contact: Investor Relations 1 888 381 7923 or Brendan Brennan Chief Financial Officer + 353 1 291 2000 Jonathan Curtain Vice President Corporate Finance and Investor Relations + 353 1 291 2000 All at ICON.

ICON/ICLR-F

View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005787/en/

CONTACT: Investor Relations 1 888 381 7923 or Brendan Brennan Chief Financial Officer + 353 1 291 2000 Jonathan Curtain Vice President Corporate Finance and Investor Relations + 353 1 291 2000